Gyre Therapeutics, Inc. 8-K Report: Year-End Insights & Updates

Based on the provided section of the financial report, here are the key information and insights extracted:

1. Company Information:

• Name: Gyre Therapeutics, Inc.
• CIK (Central Index Key): 0001124105
• Exchange: NASDAQ
• Ticker Symbol: GYRE
• Address: 12770 High Bluff Drive, Suite 150, San Diego, CA 92130
• Phone Number: 619-949-3681

2. Filing Details:

• Form Type: 8-K (Current Report)
• Filing Date: December 31, 2024
• Entity Type: Corporation
• State of Incorporation: Delaware (DE)
• SEC File Number: 000-51173
• EIN (Employer Identification Number): 56-2020050

3. Reporting Period:

• Start Date: December 31, 2024
• End Date: December 31, 2024
• The report appears to be for a single day, suggesting it may contain information about a significant event or update.

4. Security Information:

• Class of Securities: Common Stock

Insights:

• The filing is an 8-K form, which typically indicates that significant corporate events or changes have occurred, warranting disclosure to investors.
• The company is publicly traded on NASDAQ under the ticker GYRE, suggesting it is subject to rigorous SEC reporting requirements.
• The specified date for the report (December 31, 2024) indicates it is likely providing timely information regarding year-end financials or other critical company developments.

This summary encapsulates the essential aspects of the financial report provided, highlighting the company's identity, reporting details, and implications for stakeholders.